Reversion-induced LIM interaction with Src reveals a novel Src inactivation cycle

Journal of Cell Biology

Volumn 184, Issue 6, 2009, Pages 785-792

  Zhang, Yongjun ^a   Tu, Yizeng ^a   Zhao, Jianping ^a   Chen, Ka ^a   Wu, Chuanyue ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIM PROTEIN; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 13; PROTEIN TYROSINE KINASE; DNA BINDING PROTEIN; HYBRID PROTEIN; PDLIM4 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PTPN13 PROTEIN, HUMAN;

ARTICLE; CONTROLLED STUDY; EPIGENETICS; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVERTANT; BINDING SITE; CELL PROLIFERATION; CELL STRAIN HCT116; COLON TUMOR; DRUG ANTAGONISM; ENZYME ACTIVATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PROTEIN TERTIARY STRUCTURE;

BINDING SITES; CELL PROLIFERATION; COLONIC NEOPLASMS; DNA-BINDING PROTEINS; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HCT116 CELLS; HUMANS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 13; RECOMBINANT FUSION PROTEINS; SRC-FAMILY KINASES; TRANSFECTION;

EID: 64049113181     PISSN: 00219525     EISSN: 00219525     Source Type: Journal    
DOI: 10.1083/jcb.200810155     Document Type: Article

References (33)

1. Aligayer, H., D.D. Boyd, M.M. Heiss, E.K. Abdalla, S.A. Curley, and G.E. Gallick. 2002. Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis. Cancer. 94:344-351.
2. Bolen, J.B., A. Veillette, A.M. Schwartz, V. DeSeau, and N. Rosen. 1987. Activation of pp60c-src protein kinase activity in human colon carcinoma. Proc. Natl. Acad. Sci. USA. 84:2251-2255.
3. Boumber, Y.A., Y. Kondo, X. Chen, L. Shen, V. Gharibyan, K. Konishi, E. Estey, H. Kantarjian, G. Garcia-Manero, and J.P. Issa. 2007. RIL, aLIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis. CancerRes. 67:1997-2005.
4. Cartwright, C.A., M.P. Kamps,A.I. Meisler, J.M. Pipas, andW. Eckhart. 1989. pp60c-src activation in human colon carcinoma. J. Clin. Invest. 83:2025-2033.
5. Cartwright, C.A., A.I. Meisler, and W. Eckhart . 1990 . Activation of the pp60c-srcprotein kinase is an early event in colonic carcinogenesis. Proc. Natl. Acad.Sci. USA. 87:558-562.
6. Cuppen, E., H. Gerrits, B. Pepers, B. Wieringa, and W. Hendriks. 1998. PDZ motifs in PTP-BL and RIL bind to internal protein segments in the LIM domain protein RIL. Mol. Biol. Cell. 9:671-683.
7. DeSeau,V., N. Rosen, and J.B. Bolen. 1987. Analysis of pp60c-src tyrosine kinase activity and phosphotyrosyl phosphatase activity in human colon carcinoma and normal human colon mucosal cells. J. Cell. Biochem. 35:113-128.
8. Dromard, M., G. Bompard, M. Glondu-Lassis, C. Puech, D. Chalbos, and G. Freiss. 2007. The putative tumor suppressor gene PTPN13/PTPL1 induces apoptosis through insulin receptor substrate-1 dephosphorylation. Cancer Res. 67:6806-6813.
9. Ferracini, R., and J. Brugge. 1990. Analysis of mutant forms of the c-src gene product containing a phenylalanine substitution for tyrosine 416. Oncogene Res. 5:205-219.
10. Frame, M.C. 2004. Newest findings on the oldest oncogene; how activated src does it. J. Cell Sci. 117:989-998.
11. Gkretsi, V., Y. Zhang, Y. Tu, K. Chen, D.B. Stolz, Y. Yang, S.C. Watkins, and C. Wu. 2005. Physical and functional association of migfilin with cell-cell adhesions. J. Cell Sci. 118:697-710.
12. Gonfloni, S., A. Weijland, J. Kretzschmar, and G. Superti-Furga. 2000. Crosstalk between the catalytic and regulatory domains allows bidirectional regulation of Src. Nat. Struct. Mol. Biol. 7:281-286.
13. Kiess, M., B. Scharm, A. Aguzzi, A. Hajnal, R. Klemenz, I. Schwarte-Waldhoff, and R. Schafer. 1995. Expression of ril, a novel LIM domain gene, is down-regulated in Hras-transformed cells and restored in phenotypic re-vertants. Oncogene. 10:61-68.
14. Kmiecik, T.E., and D. Shalloway. 1987. Activation and suppression of pp60c-src transforming ability by mutation of its primary sites of tyrosine phos-phorylation. Cell. 49:65-73.
15. Kolligs, F.T., G. Hu, C.V. Dang, and E.R. Fearon . 1999 . Neoplastic transformation of RK3E by mutant beta-catenin requires deregulation of Tcf/Lef transcription but not activation of c-myc expression. Mol. Cell. Biol. 19:5696-5706.
16. Kopetz, S., A.N. Shah, and G.E. Gallick. 2007 . Src continues aging: current and future clinical directions. Clin. Cancer Res. 13:7232-7236.
17. Palmer, A., M. Zimmer, K.S. Erdmann, V. Eulenburg, A. Porthin, R. Heumann, U. Deutsch, and R. Klein. 2002. EphrinB phosphorylation and reverse signaling: regulation by Src kinases and PTP-BL phosphatase. Mol. Cell. 9:725-737.
18. Pazdrak, K., T. Adachi, and R. Alam. 1997. Src homology 2 protein tyrosine phosphatase (SHPTP2)/Src homology 2 phosphatase 2 (SHP2) tyrosine phosphatase is a positive regulator of the interleukin 5 receptor signal transduction pathways leading to the prolongation of eosinophil survival. J. Exp. Med. 186:561-568.
19. Piwnica-Worms, H., K.B. Saunders, T.M. Roberts, A.E. Smith, and S.H. Cheng. 1987. Tyrosine phosphorylation regulates the biochemical and biological properties of pp60c-src. Cell. 49:75-82.
20. Playford, M.P., and M.D. Schaller. 2004. The interplay between Src and integrins in normal and tumor biology. Oncogene. 23:7928-7946.
21. Rosen, N., J.B. Bolen, A.M. Schwartz, P. Cohen, V. DeSeau, and M.A. Israel . 1986. Analysis of pp60c-src protein kinase activity in human tumor cell lines and tissues. J. Biol. Chem. 261:13754-13759.
22. Roskoski, R. Jr. 2005. Src kinase regulation by phosphorylation and dephos-phorylation. Biochem. Biophys. Res. Commun. 331:1-14.
23. Russello, S.V., and S.K. Shore. 2004. SRC in human carcinogenesis. Front. Biosci. 9:139-144.
24. Schindler, T., F. Sicheri, A. Pico, A. Gazit, A. Levitzki, and J. Kuriyan . 1999. Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. Mol. Cell. 3:639-648.
25. Summy, J.M., and G.E. Gallick. 2003. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 22:337-358.
26. Summy, J.M., and G.E. Gallick . 2006 . Treatment for advanced tumors: Src reclaims center stage. Clin. Cancer Res. 12:1398-1401.
27. Superti-Furga, G., K. Jonsson, and S.A. Courtneidge. 1996 . A functional screen in yeast for regulators and antagonizers of heterologous protein tyrosine kinases. Nat. Biotechnol. 14:600-605.
28. Thomas, S.M., and J.S. Brugge. 1997. Cellular functions regulated by Src family kinases. Annu. Rev. Cell Dev. Biol. 13:513-609.
29. Tu, Y., S. Wu, X. Shi, K. Chen, and C. Wu. 2003. Migfilin and mig-2 link focal adhesions to filamin and the actin cytoskeleton and function in cell shape modulation. Cell.113:37-47.
30. Wang, Z., D. Shen, D.W. Parsons, A. Bardelli, J. Sager, S. Szabo, J. Ptak, N. Silliman, B.A. Peters , M.S. van der Heijden, et al. 2004. Mutational analysis of the ty-rosine phosphatome in colorectal cancers. Science. 304:1164-1166.
31. Yeatman, T.J. 2004. A renaissance for SRC. Nat. Rev. Cancer. 4:470-480.
32. Yeh, S.H., D.C. Wu, C.Y. Tsai, T.J. Kuo, W.C. Yu, Y.S. Chang, C.L. Chen, C.F. Chang, D.S. Chen, and P.J. Chen . 2006 . Genetic characterization of fas-associated phosphatase-1 as a putative tumor suppressor gene on chromosome 4q21.3 in hepatocellular carcinoma. Clin. Cancer Res. 12:1097-1108.
33. Ying, J., H. Li, Y. Cui, A.H. Wong, C. Langford, and Q. Tao. 2006. Epigenetic disruption of two proapoptotic genes MAPK10/JNK3 and PTPN13/FAP-1 in multiple lymphomas and carcinomas through hypermethylation of a common bidirectional promoter. Leukemia. 20:1173-1175.